HLA-C and neoplasm: Neoantigens, as tumor-specific antigens expressed exclusively in cancer cells, are presented by major histocompatibility complex (MHC) class I and II molecules, referred to as human leukocyte antigen (HLA) in humans and specifically recognized by T-cell receptors (TCRs), may thereby trigger a de novo immune response (3, 4).